NO20062793L - Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer - Google Patents

Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer

Info

Publication number
NO20062793L
NO20062793L NO20062793A NO20062793A NO20062793L NO 20062793 L NO20062793 L NO 20062793L NO 20062793 A NO20062793 A NO 20062793A NO 20062793 A NO20062793 A NO 20062793A NO 20062793 L NO20062793 L NO 20062793L
Authority
NO
Norway
Prior art keywords
treatment
cancer
diagnosis
inhibitory molecules
angiogenesis inhibitory
Prior art date
Application number
NO20062793A
Other languages
English (en)
Norwegian (no)
Inventor
Michel Aurrand-Lions
Beat A Lmhof
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,123 external-priority patent/US7642341B2/en
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20062793L publication Critical patent/NO20062793L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062793A 2003-11-19 2006-06-15 Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer NO20062793L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026629A EP1533617A1 (en) 2003-11-19 2003-11-19 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US10/738,123 US7642341B2 (en) 2003-12-18 2003-12-18 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
PCT/EP2004/013247 WO2005050213A1 (en) 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
NO20062793L true NO20062793L (no) 2006-08-18

Family

ID=34621557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062793A NO20062793L (no) 2003-11-19 2006-06-15 Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer

Country Status (18)

Country Link
US (1) US7790863B2 (pt)
EP (2) EP1533617A1 (pt)
JP (1) JP2007515159A (pt)
KR (1) KR101135834B1 (pt)
CN (1) CN1890567B (pt)
AT (1) ATE493657T1 (pt)
AU (1) AU2004291989B2 (pt)
BR (1) BRPI0415541B8 (pt)
CA (1) CA2546406C (pt)
DE (1) DE602004030819D1 (pt)
EA (1) EA009037B1 (pt)
ES (1) ES2358905T3 (pt)
IL (1) IL175686A (pt)
MX (1) MXPA06005523A (pt)
NO (1) NO20062793L (pt)
SG (1) SG148190A1 (pt)
WO (1) WO2005050213A1 (pt)
ZA (1) ZA200603069B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009110A (es) 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
AU2007301599B2 (en) * 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
CA2718092C (en) 2008-03-21 2019-03-19 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
CN102333875B (zh) 2009-02-27 2014-04-16 诺华股份有限公司 选择表达异源蛋白质的真核细胞的方法
EP2670772B1 (en) 2011-02-02 2016-07-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Antagonists of grasp55 for use as a medicament
WO2012160031A1 (en) * 2011-05-24 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for prognosing solid tumor outcome
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
GB201415367D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K Methods for detecting abnormalities in haemoglobin
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
RU2599545C1 (ru) * 2015-11-06 2016-10-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
EP0938505B1 (en) * 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
AU2002315404A1 (en) * 2001-07-16 2003-03-03 Eli Lilly And Company Extracellular junctional adhesion molecules
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
IL175686A0 (en) 2006-09-05
EP1533617A1 (en) 2005-05-25
KR20060130562A (ko) 2006-12-19
IL175686A (en) 2012-02-29
US20070202110A1 (en) 2007-08-30
US7790863B2 (en) 2010-09-07
BRPI0415541B1 (pt) 2018-11-27
ATE493657T1 (de) 2011-01-15
CN1890567B (zh) 2012-12-12
DE602004030819D1 (de) 2011-02-10
EP1685405A1 (en) 2006-08-02
BRPI0415541A (pt) 2006-12-26
SG148190A1 (en) 2008-12-31
CA2546406A1 (en) 2005-06-02
AU2004291989B2 (en) 2009-08-06
BRPI0415541B8 (pt) 2021-05-25
MXPA06005523A (es) 2006-12-14
ES2358905T3 (es) 2011-05-16
CN1890567A (zh) 2007-01-03
KR101135834B1 (ko) 2012-04-16
ZA200603069B (en) 2007-09-26
EA200600995A1 (ru) 2006-10-27
HK1097908A1 (en) 2007-07-06
EA009037B1 (ru) 2007-10-26
JP2007515159A (ja) 2007-06-14
WO2005050213A1 (en) 2005-06-02
AU2004291989A1 (en) 2005-06-02
CA2546406C (en) 2013-04-09
EP1685405B1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
NO20056236L (no) Behandling med anti-VEGF-antistoffer
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
MX2022002682A (es) Anticuerpos anti-cd73.
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
NO20084396L (no) Kombinasjonsterapi
EP4183806A3 (en) Glycan-interacting compounds and methods of use
NO20082167L (no) Anti-Myostatin-antistoffer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20081972L (no) Generering og profilering av fulle humane hucal gull-deriverte terapeutiske antistoffer spesifikke for human CD38
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
ZA202302392B (en) Antibodies against ilt2 and use thereof
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
ZA202110285B (en) Antibodies and methods of use
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application